KEY POINTS
- This retrospective single-institution study from the National Cancer Center, Korea, evaluated 192 patients with localized prostate cancer (cT1–T4N0M0) treated between 2010 and 2021. According to NCCN classification, 33 patients (17.2%) had low-risk, 72 (37.5%) intermediate-risk, and 87 (45.3%) high-risk disease, with a median follow-up of 90.6 months.
- All patients received definitive proton therapy to 70 Gy(RBE) in 28 fractions (2.5 Gy[RBE] per fraction). Passive scattering was used in 149 patients (77.6%) and pencil beam scanning in 43 (22.4%); elective pelvic nodal irradiation was not performed, and androgen deprivation therapy was administered to 51 patients (26.6%), including 47/87 high-risk patients (54.0%).
- The primary endpoint, ten-year biochemical failure-free survival (BFFS), was 78.5% overall, with risk-stratified rates of 100.0% for low-risk, 80.3% for intermediate-risk, and 66.6% for high-risk disease. Ten-year local progression-free survival was 91.3%, while prostate cancer-specific survival was 100% across all three risk groups; these long-term Kaplan–Meier estimates should be interpreted alongside the declining number of patients at risk.
- Biochemical recurrence occurred in 27 patients (14.1%). Among those with identifiable recurrence, 11 patients (5.7% of the full cohort) experienced intraprostatic recurrence, five (2.6%) regional nodal recurrence, and four (2.1%) distant metastases, with overlapping sites in two patients. All 11 intraprostatic recurrences occurred after passive-scattering treatment, and seven overlapped or were adjacent to the original tumor location, but the small event count and treatment-era differences prevent conclusions about technique-related failure.
- On multivariable analysis, ADT use was associated with a lower risk of biochemical failure (HR 0.333, 95% CI 0.123–0.906; p=0.031). High-risk classification was also associated with poorer biochemical control than low-risk disease (HR 10.46, 95% CI 1.39–78.81; p=0.023), although the wide confidence interval and nonstandardized selection for ADT limit interpretation of the estimated effect sizes.
- Rectal bleeding of any grade was reported in 101/192 patients (52.6%), predominantly as mild, self-limited events. Ten patients (5.2%) underwent endoscopic coagulation, contributing to the reported grade ≥3 GI toxicity rate, although some interventions were performed despite relatively mild symptoms. Grade 3 GU toxicity occurred in six patients (3.1%), including urinary bleeding or obstructive complications; no treatment-related deaths occurred.
- Planning and image guidance evolved substantially during the study period, including reductions in PTV margins from 10 mm (6 mm posteriorly) to 7 mm (4 mm posteriorly). The retrospective design, predominantly passive-scattering treatments, limited ADT use in high-risk disease, physician-reported toxicity, and absence of a photon control group mean that the study cannot establish proton superiority or isolate the effect of hypofractionation.
CLINICAL TAKEAWAY
Moderately hypofractionated proton therapy with 70 Gy(RBE) in 28 fractions was associated with durable biochemical control and relatively uncommon severe late toxicity over extended follow-up. These results provide a long-term clinical benchmark, but do not demonstrate superiority over contemporary photon radiotherapy, and the recurrence pattern and limited ADT exposure should be considered when interpreting outcomes in high-risk patients.